이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mayne Pharma Group 과거 수익 실적

과거 기준 확인 0/6

Mayne Pharma Group의 수입은 연평균 -12.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 8.4%의 비율로 증가했습니다. 매출은 연평균 25.1%의 비율로 감소해 왔습니다.

주요 정보

-0.9%

수익 성장률

0.9%

EPS 성장률

Pharmaceuticals 산업 성장	7.3%
매출 성장률	-16.6%
자기자본 수익률	-37.1%
순이익	-43.4%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Mayne Pharma Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:HG6 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	388	-169	243	20
31 Mar 24	354	-221	257	19
31 Dec 23	319	-274	272	18
30 Sep 23	251	-296	261	17
30 Jun 23	184	-317	251	16
31 Dec 22	59	-257	193	13
30 Sep 22	108	-233	187	12
30 Jun 22	157	-209	182	12
31 Mar 22	250	-151	184	15
31 Dec 21	342	-93	186	19
30 Sep 21	372	-151	179	20
30 Jun 21	401	-208	173	22
31 Mar 21	420	-232	180	22
31 Dec 20	439	-256	187	22
30 Sep 20	448	-174	194	24
30 Jun 20	457	-93	200	25
31 Mar 20	467	-196	210	26
31 Dec 19	478	-300	220	27
30 Sep 19	502	-290	231	28
30 Jun 19	525	-279	241	29
31 Mar 19	543	-118	230	27
31 Dec 18	561	43	219	25
30 Sep 18	546	-46	208	20
30 Jun 18	530	-134	197	15
31 Mar 18	526	-146	196	12
31 Dec 17	521	-158	194	8
30 Sep 17	547	-35	192	8
30 Jun 17	573	89	190	8
31 Mar 17	504	90	173	8
31 Dec 16	435	91	156	8
30 Sep 16	351	64	136	7
30 Jun 16	267	37	115	7
31 Mar 16	238	30	105	7
31 Dec 15	209	23	94	7
30 Sep 15	175	15	77	6
30 Jun 15	141	8	60	4
31 Mar 15	137	12	50	3
31 Dec 14	133	17	40	3
30 Sep 14	138	19	37	4
30 Jun 14	143	21	35	5
31 Mar 14	135	15	33	5
31 Dec 13	126	8	31	6
30 Sep 13	105	3	25	5

양질의 수익: HG6 은(는) 현재 수익성이 없습니다.

이익 마진 증가: HG6 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: HG6 은(는) 수익성이 없으며 지난 5년 동안 연간 12.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 HG6 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: HG6 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 1.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: HG6 현재 수익성이 없기 때문에 마이너스 자본 수익률( -50.05% )을 갖습니다.

Mayne Pharma Group 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기